文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

生物标志物驱动的低危骨髓增生异常肿瘤对罗米司亭缓解预测模型的前瞻性验证——EMSCO的EUROPE试验结果

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
PubMed 文献 · Leukemia · 2022-09-07

EUROPE 2期试验在EMSCO网络中评估生物标志物对低危骨髓增生异常肿瘤(LR-MDS)伴血小板减少患者单用罗米司亭(ROM)疗效的预测价值。共纳入77例LR-MDS患者,中位血小板计数25/nl,均接受ROM起始剂量750 μg每周皮下注射。32例(42%)达血小板血液学改善(HI-P),中位持续340天;中性粒细胞和红系缓解分别为3例(4%)和7例(9%)。SRSF2突变状态和基线血红蛋白水平与HI-P显著相关,未证实基线内源性血小板生成素水平和血小板输注史与HI-P的相关性。

要点

  • 77例LR-MDS伴血小板减少患者接受ROM 750 μg每周皮下注射,HI-P率42%,中位持续340天。
  • SRSF2突变状态和基线血红蛋白水平与HI-P显著相关。
  • 未证实基线内源性血小板生成素水平和血小板输注史与HI-P相关。

核心结论

  • 研究证实ROM在LR-MDS患者中的安全性和有效性,可能有助于更好定义高缓解可能性的患者亚组。

研究设计与样本

  • EUROPE 2期试验,在EMSCO网络内开展,纳入77例LR-MDS伴血小板减少患者,中位血小板计数25/nl,所有患者接受ROM起始剂量750 μg每周皮下注射。

主要发现

  • 32例(42%)达HI-P,中位持续340天;中性粒细胞缓解3例(4%),红系缓解7例(9%)。
  • SRSF2突变状态和基线血红蛋白水平与HI-P显著相关。
  • 未证实基线内源性血小板生成素水平和血小板输注史与HI-P相关。
  • 对SRSF2等突变变位等位基因频率的序贯分析未显示ROM对缓解者和非缓解者的克隆演化有影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the 'European Myelodysplastic Neoplasms Cooperative Group' (EMSCO) network. A total of 77 patients with LR-MDS and a median platelet count of 25/nl were included, all patients received ROM at a starting dose of 750 μg by SC injection weekly. Thirty-two patients (42%) achieved a hematologic improvement of platelets (HI-P) with a median duration of 340 days. Neutrophil (HI-N) and erythroid (HI-E) responses were observed in three (4%) and seven (9%) patients, respectively. We could not confirm previous reports that HI-P correlated with baseline endogenous thrombopoietin levels and platelet transfusion history, but SRSF2 mutation status and hemoglobin levels at baseline were significantly linked to HI-P. Sequential analysis of variant allelic frequency of mutations like SRSF2 did not reveal an impact of ROM on clonal evolution in both responders and non-responders. In summary, our study confirms the safety and efficacy of ROM in LR-MDS patients and may allow to better define subgroups of patients with a high likelihood of response.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kubasch AS, Giagounidis A, Metzgeroth G, et al. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO. Leukemia. 2022. PMID: 36071100. doi:10.1038/s41375-022-01669-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。